TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01063569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Cortef (hydrocortisone)
Description: Continuous Subcutaneous Hydrocortisone infusion via insulin pump. Doses adjusted to body surface area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortef (hydrocortisone)
Description: Oral treatment 3 times a day. Weight adjusted doses.
Study: NCT02095457

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Frequent monitoring and feedback
Description: In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Frequent monitoring and feedback
Description: In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
Study: NCT00434941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT02869009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study: NCT01959919

Intervention type: DEVICE
Intervention: Refacto FusENGO
Description: Dosage will be chosen by PI based on patient condition.
Study: NCT02933320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination of BI-1206 with rituximab expansion phase
Description: BI-1206 in combination with rituximab at the RP2D.
Study: NCT04238585

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mobile messaging
Description: Mobile health messages
Study: NCT00476203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Instructor-led yoga classes 1/time per week + 4 days of home practice

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed yoga classes
Description: Delayed yoga classes (after 6 months) offered \[wait list control group\]
Study: NCT01739556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Regimen Modification (aspirin or ticagrelor)
Study: NCT03315403

Intervention type: DIAGNOSTIC_TEST
Intervention: LytA targeted quantitative polymerase chain reaction (qPCR)
Description: LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: LytA targeted quantitative polymerase chain reaction (qPCR)
Description: LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: LytA targeted quantitative polymerase chain reaction (qPCR)
Description: LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: LytA targeted quantitative polymerase chain reaction (qPCR)
Description: LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: LytA targeted quantitative polymerase chain reaction (qPCR)
Description: LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)
Study: NCT04355637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Description: adding budesonide to standard of care for pneumonia in COVID19 positive patients
Study: NCT01436409

Intervention type: OTHER
Group type: OTHER
Intervention: echography
Description: echography during labor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: echography
Description: echography during labor
Study: NCT00886613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: Two doses of 0.65 mL V212 subcutaneous injection administered at Day 1 and Day 31

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Zostavax™
Description: Two doses of 0.65 mL Zostavax™ subcutaneous injection administered at Day 1 and Day 31

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Two doses of 0.65 mL subcutaneous injection of placebo administered at Day 1 and Day 31

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VZV Skin Test
Description: Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VZV Skin Test
Description: Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VZV Skin Test
Description: Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.
Study: NCT01642940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 10mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90mg twice a day
Study: NCT00415675

Intervention type: PROCEDURE
Intervention: Motion CT Scans
Description: A total of up to 12 scanning sessions used to understand how the tumor and other organs move while breathing.
Study: NCT04238585

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile messaging
Description: Mobile health messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile messaging
Description: Mobile health messages
Study: NCT02844764

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [StroMed + platelet rich plasma (PRP)]
Description: Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated with direct injections to the joint with Platelet Rich Plasma processed by RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Day 7, 14 and 30 \[PRP\]
Study: NCT03613103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Description: Intubation with videolaryngoscopy with highly curved blade

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: Intubation with direct laryngoscopy with macintosh blade
Study: NCT03425292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: concomitant and 5-day adjuvant temozolomide

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conformal brain radiation therapy
Description: standard radiation therapy for newly diagnosed glioblastoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 240 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 240 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 240 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 240 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 1 mg/kg IV every 6 weeks (or every 8 weeks when nivolumab is administered every 4 weeks) for a maximum of 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 1 mg/kg IV every 6 weeks (or every 8 weeks when nivolumab is administered every 4 weeks) for a maximum of 4 doses
Study: NCT04014673

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral : Characterization
Description: Behavioral scales and neuropsychological tests; MRI, SPECT/PET

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral : Characterization
Description: Behavioral scales and neuropsychological tests; MRI, SPECT/PET

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral : Characterization
Description: Behavioral scales and neuropsychological tests; MRI, SPECT/PET
Study: NCT02282358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat
Study: NCT01638364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alcoholic beverage
Description: An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks. The beverage will be consumed over a period of 15 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: non-alcoholic beverage
Description: This beverage will be a mixture of orange juice and tonic water. The beverage will be consumed over a period of 15 minutes.
Study: NCT03658057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: whether neuromuscular blockade by administering rocuronium is performed or not.
Study: NCT01561729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RightSpot pH Indicator
Description: The RightSpot pH Indicator device is used to confirm proper placement of all types of gastric tubes used for gastric rest, suction, or medicating/feeding by measuring the pH of stomach aspirate. This device is intended for 1 (one) SINGLE USE. The probability of proper placement is higher when the pH is less than or equal to 4.5 and if aspirate has a typical gastric fluid appearance (grassy green, brown, colorless- with possible shreds of off-white mucus or sediment).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chest radiograph
Description: Chest radiograph will be taken after tube placement to verify proper positioning of the nasogastric or orogastric tube.
Study: NCT04410029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthwise Decision Aid
Description: Healthwise, a non-profit company that develops health content and patient information for hospitals, has created a decision aid for EPL management that is available through the EPIC Systems, an electronic medical record. Participants will be given this decision aid after EPL diagnosis and prior to options consultation with a provider.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control informational handout
Description: Participants randomized to the control arm will be given an informational handout of treatment options after EPL diagnosis and prior to options consultation with a provider.
Study: NCT03610360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MesoPher
Description: Subjects in Arm A will undergo leukapheresis to obtain monocytes from which dendritic cells will be generated. These dendritic cells will be loaded in vitro with an allogeneic tumor cell lysate (PheraLys). Treatment with autologous dendritic cells loaded with PheraLys is called MesoPher
Study: NCT03425292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 1 mg/kg IV every 6 weeks (or every 8 weeks when nivolumab is administered every 4 weeks) for a maximum of 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 1 mg/kg IV every 6 weeks (or every 8 weeks when nivolumab is administered every 4 weeks) for a maximum of 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 5 mg/kg IV every 2 weeks (up to 10 mg/kg at treating physician's discretion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-day Temozolomide
Description: 150 mg/m\^2 oral, once daily on Days 1-5 of each 28-day cycle (stepwise titration every cycle up to 200 mg/m\^2 permitted)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-day Temozolomide
Description: 150 mg/m\^2 oral, once daily on Days 1-5 of each 28-day cycle (stepwise titration every cycle up to 200 mg/m\^2 permitted)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-day Temozolomide
Description: 100 mg/m\^2 oral, once daily on Days 2-6 of each 6 week course (stepwise titration every cycle up to 200 mg/m\^2 permitted)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: 100 mg/m\^2 oral, on Day 1 of each 6 week course

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Description: nivolumab 300 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
Study: NCT02416635

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Study: NCT01033461

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium and probiotic
Description: the subjects consumed for 4 weeks a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 and a bread enriched with 1 g pentacalcium phosphate per day
Study: NCT02440178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Study: NCT02512939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood test, not yet marketed, no trade name
Description: blood test using the new TB diagnostic test
Study: NCT02070211

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 PUFAs
Description: 4 capsules (2 in the morning; 2 in the evening) for a period of 12 weeks. The active treatment is a supplement of yellow gelatine 0.625 g capsules containing concentrated marine fish oil. The daily dose of 4 capsules will provide approximately 700 mg of eicosapentaenoic acid (EPA, 20:5n3), 480 mg of docosahexaenoic acid (DHA, 22:6n3), and 7.6 mg of Vitamin E.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard care includes management by a psychiatrist or resident psychiatrist and non-neuroleptic pharmacotherapy as clinically indicated. Specifically, Cognitive-behavioural therapy (CBT) embedded within case management will be administered. The CBT will be based on the models developed at the PACE Clinic in Melbourne, in the EDIE trial, and in Cologne, as these have proven to be effective in RCTs. The number of sessions delivered will be captured for each client. In addition, fidelity will be monitored by therapists rating their own sessions on an established checklist of therapeutic interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care includes management by a psychiatrist or resident psychiatrist and non-neuroleptic pharmacotherapy as clinically indicated. Specifically, Cognitive-behavioural therapy (CBT) embedded within case management will be administered. The CBT will be based on the models developed at the PACE Clinic in Melbourne, in the EDIE trial, and in Cologne, as these have proven to be effective in RCTs. The number of sessions delivered will be captured for each client. In addition, fidelity will be monitored by therapists rating their own sessions on an established checklist of therapeutic interventions.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 capsules of 0.7g of paraffin oil (which is not absorbed by the gastrointestinal tract) per day.
Study: NCT01033461

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: the subjects consumed a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 for 4 weeks
Study: NCT01644591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study: NCT00839930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 mg Tablets
Description: 1 x 50 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pletal®
Description: 1 x 50 mg, single-dose tablet
Study: NCT01282398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: The experimental group will take 40 mg each 24 hours for at least two years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the control group wiil take placebo pills for at least two years.
Study: NCT02133872

Intervention type: DRUG
Group type: OTHER
Intervention: Minocycline dose escalation
Description: Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/\> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/\> 5mm Hg BP subjects will receive minocycline 200 mg.
Study: NCT01798225

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and placebo pills.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and Doxycycline 100mg x 14 pills (to be taken one a day for 14 days)
Study: NCT01893450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Study: NCT04576754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WB001
Description: The WB001 treatment consists of PPD-specific psychoeducational lessons and CBT-specific skills or tools. The lessons teach PPD-specific information to normalize and contextualize postpartum experiences, as well as provide information on effective mood management and mental health promotion in the context of having recently given birth. Patients complete up to 30 psychoeducational lessons. In addition, patients access and apply core CBT-based tools upon endorsing a negative mood. These tools are core to CBT and are considered transdiagnostic. Examples include thought challenging, behavioral activation, mindfulness, and self-care.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Educational
Description: The Comparison Condition provides educational only material about various mental and physical topics, delivered in an interactive smartphone application that is accessible anytime of day.
Study: NCT02826681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectafer® (Ferric Carboxymaltose - FCM)
Description: Intravenous Iron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal Saline)
Description: Normal Saline Solution
Study: NCT04306120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Rehabilitation Therapy
Description: The protocol included range of motion, ambulation, endurance, strengthening, reconditioning exercise, and home program education according to therapists' plans and the patients' ability.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Rehabilitation Therapy
Description: The protocol included range of motion, ambulation, endurance, strengthening, reconditioning exercise, and home program education according to therapists' plans and the patients' ability.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Rehabilitation Therapy
Description: The protocol included range of motion, ambulation, endurance, strengthening, reconditioning exercise, and home program education according to therapists' plans and the patients' ability.
Study: NCT01030809

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Algorithm for Crohn's Disease
Description: Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
Study: NCT01033461

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the subjects consumed a yoghurt drink without L. paracasei LPC 37 and a bread without pentacalcium phosphate
Study: NCT02603549

Intervention type: OTHER
Intervention: Pituitary panel will be drawn pre-op and post-op for all patients.
Study: NCT03220633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB-346

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00910273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: etanercept 50 mg/week
Study: NCT00561769

Intervention type: DRUG
Intervention: Norditropin pen
Description: 12 IU per day
Study: NCT01498978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02416635

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.